Naproxen Sodium is a drug marketed by Bionpharma Inc, Puracap Pharm Llc, Actavis Labs Fl Inc, Able, Amneal Pharms Ny, Aurobindo Pharma Ltd, Contract Pharmacal, Dr Reddys Labs Inc, Dr Reddys Labs Ltd, Glenmark Pharms Ltd, Granules India, Hamilton Pharms, Hikma, Ivax Sub Teva Pharms, Lnk Intl Inc, Marksans Pharma, Mylan, Perrigo, Pld Acquisitions Llc, Pliva, Purepac Pharm, Roxane, Sandoz, Sun Pharm Inds Ltd, Teva, Teva Pharms, and Watson Labs and, and is included in thirty-five NDAs. It is available from one hundred and forty-six suppliers. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has ten patent family members in thirteen countries.
The generic ingredient in NAPROXEN SODIUM is naproxen sodium; pseudoephedrine hydrochloride. One hundred and forty-six suppliers are listed for this compound. Additional details are available on the naproxen sodium; pseudoephedrine hydrochloride profile page.
Copyright © DrugPatentWatch. Originally published at New patent for Bionpharma Inc drug NAPROXEN SODIUM